Melissa Daubert, MD
Cardiovascular Disease · Henderson, NCNPI 1558553834
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,800 of the $7,050 with a category attached, or 68.1%. 3 manufacturers reported payments, led by Bayer at 46.8% of the total.
Across 5 payments — averaging $1410.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- ZOLL Circulation Inc$2K
Across 85 payments — averaging $29,877 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Heartflow, Inc.$2.5M
What the payments were for
- Consulting fees$4,80068%
- Speaking & faculty fees$2,25032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 2 | $3,300 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $2,250 |
| ZOLL Circulation Inc | 1 | $1,500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$2,250
- TherOx DS2 Console$1,500
- Catheter$1,500
- Downstream Cartridge$1,500
How this compares
$7,050 in reported general payments places this provider in the 70th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $14,823 |
| Metoprolol Succinate | 39 | $453 |
| Amlodipine Besylate | 28 | $299 |
| Rosuvastatin Calcium | 35 | $253 |
| Atorvastatin Calcium | 24 | $220 |
| Carvedilol | 17 | $160 |
| Lisinopril | 24 | $92 |
| Losartan Potassium | 15 | $68 |
| Furosemide | 11 | $36 |
| Hydrochlorothiazide | 14 | $22 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Henderson
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
- Sean PokorneyMorganton$477K
- Adrian HernandezDurham$409K
- Sanjeev GulatiCharlotte$406K
- Richard BrowneCharlotte$379K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.